Medtronic
Symplicity HTN-3 Clinical Trial

Caution: Investigational device. Limited by United States law to investigational use.

The Medtronic Investigational Therapy — Renal Denervation

One of the body's primary methods for controlling blood pressure involves the sympathetic nervous system. This system includes the major organs that are responsible for regulating blood pressure: the brain, the heart, the kidney and the blood vessels themselves. One key player in long term blood pressure regulation is the kidney. Renal nerves communicate information from the kidney to the brain, and vice versa. In people with hypertension, the renal nerves are hyperactive, which raises blood pressure and contributes to heart, kidney and blood vessel damage.

Renal Denervation (RDN) treatment is being studied in a clinical trial to learn whether renal denervation is a safe and effective treatment option to lower blood pressure for certain patients with uncontrolled hypertension. The SYMPLICITY HTN U.S. Trial Program will attempt to disrupt the hyperactive nerves by applying brief radio frequency (RF) energy near the nerves with an experimental medical device.

A single procedure is performed by inserting a tube in the groin and placing the device in the artery leading to the kidney. Using RF, multiple treatments are performed in each artery to disrupt the hyperactive nerves. Following treatment, the device is removed.

Learn more about this investigational therapy and our clinical trials. To see if you may qualify for one of our trials, please take this short survey or connect with a participating doctor.

Talk with your doctor about potential risks associated with renal denervation.